pubmed-article:1587429 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1587429 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:1587429 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
pubmed-article:1587429 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
pubmed-article:1587429 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
pubmed-article:1587429 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
pubmed-article:1587429 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:1587429 | pubmed:dateCreated | 1992-6-19 | lld:pubmed |
pubmed-article:1587429 | pubmed:abstractText | In a randomized, controlled trial of recombinant interferon alfa-2b with or without prednisone priming in Chinese adults with chronic hepatitis B virus infection, stratified randomization for pretreatment serum alanine aminotransferase levels was done. Partial or complete antiviral responses were achieved in 17 (21.5%) of 79 treated patients and 3 (8.3%) of 36 controls (P = 0.14). The response to interferon treatment was significantly better in those who had elevated pretreatment transaminase levels and comparable to that reported in white patients [15 (38.5%) of 39 patients compared with 2 (5%) of 40 who had normal pretreatment transaminase levels (P = 0.0005)]. The spontaneous seroconversion rate was also higher among the controls with elevated transaminase levels [3 (18.8%) of 16 compared with 0 of 20 with normal transaminase levels], but this difference was not statistically significant (P = 0.16). Among the interferon-treated patients, prednisone priming appeared to have a marginal benefit over treatment with interferon alone in patients with elevated transaminase levels (43% vs. 33%), but not in those with normal transaminase levels (0% vs. 9.5%). It was confirmed that Chinese patients with normal transaminase levels respond very poorly to interferon alfa therapy. However, the response was significantly better in patients with elevated transaminase levels. | lld:pubmed |
pubmed-article:1587429 | pubmed:language | eng | lld:pubmed |
pubmed-article:1587429 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:1587429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1587429 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1587429 | pubmed:month | Jun | lld:pubmed |
pubmed-article:1587429 | pubmed:issn | 0016-5085 | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:LowA GAG | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:LaiC LCL | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:WuP CPC | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:LauderI JIJ | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:LinJ HJH | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:NgC PCP | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:ChungH THT | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:WongL SLS | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:LeungE KEK | lld:pubmed |
pubmed-article:1587429 | pubmed:author | pubmed-author:MaO COC | lld:pubmed |
pubmed-article:1587429 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1587429 | pubmed:volume | 102 | lld:pubmed |
pubmed-article:1587429 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1587429 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1587429 | pubmed:pagination | 2091-7 | lld:pubmed |
pubmed-article:1587429 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:meshHeading | pubmed-meshheading:1587429-... | lld:pubmed |
pubmed-article:1587429 | pubmed:year | 1992 | lld:pubmed |
pubmed-article:1587429 | pubmed:articleTitle | A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. | lld:pubmed |
pubmed-article:1587429 | pubmed:affiliation | Department of Medicine, University of Hong Kong. | lld:pubmed |
pubmed-article:1587429 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1587429 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:1587429 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:1587429 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1587429 | lld:pubmed |